 |
|
Against pulmonary fibrosis
March 06, 2006The biotech companies Digna Biotech and Biotherapix have signed an agreement to jointly apply their patented products towards the development of a treatment for pulmonary fibrosis. Digna Biotech is the commercial entity responsible for developing the intellectual property (patents) generated by the CIMA of the University of Navarra in its preclinical, clinical and commercial research.
The focal points of this agreement are the M3 protein owned by Biotherapix and the p17 peptide from Digna Biotech. It is hoped that these two compounds can work in common, taking advantage of the chemokyne inhibiting activity of M3 and the specific TGF-beta1 inhibiting activity of p17. Both TGF-beta1 as well as the chemokynes are key molecules in various inflammatory and degenerative processes. The researchers believe that the combined action of M3 and p17 will allow the development of a viable therapeutic alternative for treating pulmonary fibrosis.
The necessary studies for the development of the treatment us the p17 peptide and the M3 protein will be preferentially performed in centers of the University of Navarra: the CIMA, the University Hospital and the CIFA (Center for Research in Applied Pharmacobiology).
Combination of the p17 peptide and the M3 protein
The causes of pulmonary fibrosis are poorly known; this disease is characterized by an abnormal accumulation of collagen fibers in the lung, which causes structural deterioration. This deterioration causes progressive scarring in the lungs, which impedes the uptake of oxygen into the bloodstream, and thus impedes respiration. The European health authorities currently consider that pulmonary fibrosis is a rare or uncommon disease, with a prevalence of from 13 cases (in men) to 20 cases (in women) per 100,000 persons.
There do not currently exist effective treatments for this disease. The current treatments are based on the administration of oxygen and anti-inflammatories (glucocorticoids), some associated with immunosuppression and others not. These therapies have had limited success in reduction the progress of the fibrosis, and a contribute little to improving the quality of life of those affected.
The p17 peptide has demonstrated its effectiveness in the animal model which best reproduces pulmonary fibrosis. Currently, research is underway to confirm these findings with other models, and to begin toxicological studies. M3, on the other hand, is a protein of viral origin which has demonstrated its neutralizing effect against a wide set of molecules from the chemokyne family. Biotherapix is researching the use of derivatives of this molecule in order to slow certain inflammatory processes in which chemokynes play a key role. The M3 protein has shown advantages over other biological therapeutic molecules, such as its inhibiting activity against multiple chemokynes, as well as its low toxicity.
Elhuyar Fundazioa
Combination of the p17 peptide and the M3 protein
The causes of pulmonary fibrosis are poorly known; this disease is characterized by an abnormal accumulation of collagen fibers in the lung, which causes structural deterioration. This deterioration causes progressive scarring in the lungs, which impedes the uptake of oxygen into the bloodstream, and thus impedes respiration. The European health authorities currently consider that pulmonary fibrosis is a rare or uncommon disease, with a prevalence of from 13 cases (in men) to 20 cases (in women) per 100,000 persons.
There do not currently exist effective treatments for this disease. The current treatments are based on the administration of oxygen and anti-inflammatories (glucocorticoids), some associated with immunosuppression and others not. These therapies have had limited success in reduction the progress of the fibrosis, and a contribute little to improving the quality of life of those affected.
The p17 peptide has demonstrated its effectiveness in the animal model which best reproduces pulmonary fibrosis. Currently, research is underway to confirm these findings with other models, and to begin toxicological studies. M3, on the other hand, is a protein of viral origin which has demonstrated its neutralizing effect against a wide set of molecules from the chemokyne family. Biotherapix is researching the use of derivatives of this molecule in order to slow certain inflammatory processes in which chemokynes play a key role. The M3 protein has shown advantages over other biological therapeutic molecules, such as its inhibiting activity against multiple chemokynes, as well as its low toxicity.
Elhuyar Fundazioa
Pulmonary Fibrosis Current Events and Pulmonary Fibrosis News RSSCommon weed could provide clues on aging and cancer
A common weed and human cancer cells could provide some very uncommon details about DNA structure and its relationship with telomeres and how they affect cellular aging and cancer, according to a team led by scientists from Texas A&M University and the University of Cincinnati (UC).
New data: Hospital imaging centers poised to pull back, hitting patients hardest in rural areas
Survivors and patients with cancers and heart disease, along with patient advocate organizations and physicians, today urged policymakers to enhance early diagnosis of deadly diseases by preserving access to advanced imaging, such as MRI and CT scans, in final health care reform legislation.
Pitt team first to profile genes in acutely ill idiopathic pulmonary fibrosis patients
The first findings from a one-of-a-kind, patient-driven effort to provide lung tissue for research might help doctors predict when patients with idiopathic pulmonary fibrosis (IPF) are becoming dangerously ill and also could point the way to interventions that could sustain them until life-saving transplants can be performed.
Protein may be strongest indicator of rare lung disease, study shows
Researchers at the University of Cincinnati (UC) have discovered a protein in the lungs that can help in determining progression of the rare lung disease Idiopathic Pulmonary Fibrosis (IPF).
Large clinical trial finds pirfenidone may help lung function in IPF patients
A large, well-controlled, multi-national clinical trial program has demonstrated the effectiveness and safety of what may become the first FDA-approved medicine for idiopathic pulmonary fibrosis, or IPF.
UT Southwestern researchers identify gene linked to inherited form of fatal lung disease
Researchers at UT Southwestern Medical Center have determined that a mutation in a gene known for its role in defending the lungs against invading pathogens is responsible for some inherited cases of a lethal lung disease affecting older adults. The same mutation may also be associated with lung cancer, the researchers said.
Double threat: Deadly lung disease also linked to heart attacks
Patients with idiopathic pulmonary fibrosis (IPF) are three times as likely to experience severe coronary events-including heart attacks-than people without the disease.
Note to people with scarred and stiffened lungs: Monitor your sleep before severe fatigue sets in
Family, friends and neighbors remember Lisa Sandler Spaeth as an active mother of two in Potomac, Md., with a lot on the go, juggling her son's baseball games and her daughter's horseback-riding lessons with numerous committee obligations, organizing women's activities at her local synagogue.
Biomarkers identified for idiopathic pulmonary fibrosis
The first evidence of a distinctive protein signature that could help to transform the diagnosis and improve the monitoring of the devastating lung disease idiopathic pulmonary fibrosis (IPF) is being reported by University of Pittsburgh School of Medicine researchers in this month's edition of PLoS Medicine, an open-access journal of the Public Library of Science.
UCSF marks a milestone with 500th transplant in heart and lung program
UCSF marked a milestone this week with the 500th procedure in its Thoracic Transplant Program, which specializes in transplantation of the heart and lung.
More Pulmonary Fibrosis Current Events and Pulmonary Fibrosis News Articles
 |
The Official Patient's Sourcebook on Idiopathic Pulmonary Fibrosis by James N. Parker (Author) This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to idiopathic pulmonary fibrosis (also alveolocapillary block; cryptogenic fibrosing alveolitis; diffuse fibrosing alveolitis; fibrosing alveolitis; Hamman-Rich syndrome; idiopathic diffuse interstitial pulmonary fibrosis), from the essentials to the most advanced areas of research. The title of this book includes the word official. This reflects the fact that the sourcebook draws from public, academic, government, and peer-reviewed research. Selected readings from various... |
 |
Understanding Lung Disease: Pulmonary Fibrosis (Home Use) Part of the award winning public television series Healthy Body/Healthy Mind. Pulmonary Fibrosis is a set of diseases that cause progressive scarring inside the lungs. Over time the lungs are slowly replaced with scar tissue, which causes airways to restrict airflow, making it difficult to breath and to get enough oxygen. Doctors, patients and researchers are hoping clinical trials will lead to a drug that prevents lung function from worsening ultimately allowing patients to live longer. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Pulmonary Fibrosis Awareness Ribbon Mouse Pad by MyHeritageWear.com The Pulmonary Fibrosis Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Pulmonary Fibrosis Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Pulmonary Fibrosis Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
![Thorwald / Pulmonary Fibrosis [Explicit]](http://ecx.images-amazon.com/images/I/41anx1tCcwL._SL160_.jpg) |
Thorwald / Pulmonary Fibrosis [Explicit] Thorwald / Pulmonary Fibrosis (Primary Contributor) |
 |
Understanding Lung Disease: Pulmonary Fibrosis Directed By: (c) Information Television Network |
 |
Idiopathic Pulmonary Fibrosis Medical Guide by Qontro Medical Guides (Author) The Idiopathic Pulmonary Fibrosis Medical Guide is a publication which has been designed to better help readers understand Idiopathic Pulmonary Fibrosis. This Qontro Medical Guide has been designed with the reader in mind, and is a useful information source for readers at all levels looking to learn more about Idiopathic Pulmonary Fibrosis. The Idiopathic Pulmonary Fibrosis Medical Guide is highly recommended for those interested in understanding and learning more about Idiopathic Pulmonary Fibrosis. |
 |
Advances in Pulmonary Fibrosis by John Simpson (Author), Ann Millar (Author) Recent years have seen renewed interest in diffuse parenchymal lung diseases (DPLDs), which were formerly referred to as interstitial lung diseases (ILDs). This is reflected in the publication of many important and groundbreaking papers in this field. Knowledge, and easy access to it, is the key to understanding pulmonary fibrosis. Providing reviews of the published medical literature of the past year, Advances in Pulmonary Fibrosis summarizes some of the most important new developments in the field. The book has been carefully designed so that key messages can be extracted by reading only the Background and Interpretations sections of each chapter. Providing more detailed information, the Comment sections generally start with an outline of the methods used, followed by a more... |
 |
Chronic Respiratory Disorders (118) CD-ROM by Concept Media, a division of Jobson Medical Information LLC 5 CD series including these programs: [118.1] Chronic Obstructive Pulmonary Disease; [118.2] Cystic Fibrosis; |
|
|
Compres Of Pulmonary Parenchyma [Explicit] Thorwald / Pulmonary Fibrosis (Primary Contributor) |
|
Understanding Lung Disease: Pulmonary Fibrosis Starring: Information Television Network |
| © 2009 BrightSurf.com |